Evommune EVMN Income (Loss) from Equity Method Investments, Net of Dividends or Distributions

Income (Loss) from Equity Method Investments, Net of Dividends or Distributions at other companies

RadNetRDNT

$1.07M-58.9%

American International GroupAIG

$0-100%

General MotorsGM

$266M+155%

Ford Motor CompanyF

$28M+100%

Pagaya TechnologiesPGY

$1.29M+429%

NXP SemiconductorsNXPI

-$4M0.0%

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's income (loss) from equity method investments, net of dividends or distributions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's income (loss) from equity method investments, net of dividends or distributions?: Evommune (EVMN) reported income (loss) from equity method investments, net of dividends or distributions of $77.05K in Q1 2026.